Amy Guillaumet-Adkins

Amy Guillaumet-Adkins

Auto-generated profile, based on publicly available information

Amy Guillaumet-Adkins

Epigenomics Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
PAPraveen Anand
Praveen Anand
AGAmy Guillaumet-Adkins
Amy Guillaumet-Adkins
VDValeriya Dimitrova
Valeriya Dimitrova
HYHuiyoung Yun
Huiyoung Yun
Yotam DrierYotam Drier
Yotam Drier
BKBirgit Knoechel
Birgit Knoechel
Lineage plasticity and stemness have been invoked as causes of therapy resistance in cancer, because these flexible states allow cancer cells to dedifferentiate and alter their dependencies. We investigated such resistance mechanisms in relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) carrying activating NOTCH1 mutations via full-length single-cell RNA sequencing (scRNA-seq) of malignant and microenvironmental cells. We identified 2 highly distinct stem-like states that critically differed with regard to cell cycle and oncogenic signaling. Fast-cycling stem-like leukemia cells demonstrated Notch activation and were effectively eliminated in patients by Notch inhibition, whereas slow-cycling stem-like cells were Notch independent and rather relied on PI3K signaling, likely explaining the poor efficacy of Notch inhibition in this disease. Remarkably, we found that both stem-like states could differentiate into a more mature leukemia state with prominent immunomodulatory functions, including high expression of the LGALS9 checkpoint molecule. These cells promoted an immunosuppressive leukemia ecosystem with clonal accumulation of dysfunctional CD8+ T cells that expressed HAVCR2, the cognate receptor for LGALS9. Our study identified complex interactions between signaling programs, cellular plasticity, and immune programs that characterize ETP-ALL, illustrating the multidimensionality of tumor heterogeneity. In this scenario, combination therapies targeting diverse oncogenic states and the immune ecosystem seem most promising to successfully eliminate tumor cells that escape treatment through coexisting transcriptional programs.

15 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
TCTim H. H. Coorens
Tim H. H. Coorens
AGAmy Guillaumet-Adkins
Amy Guillaumet-Adkins
RKRothem Kovner
Rothem Kovner
RLRebecca L. Linn
Rebecca L. Linn
VRVictoria H. J. Roberts
Victoria H. J. Roberts
PHPatrick M. Van Hoose
Patrick M. Van Hoose

27 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NINam Gyu Im
Nam Gyu Im
AGAmy Guillaumet-Adkins
Amy Guillaumet-Adkins
MWMegha Wal
Megha Wal
ARAnna J. Rogers
Anna J. Rogers
JFJulia Frede
Julia Frede
BKBirgit Knoechel
Birgit Knoechel
Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell–leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity. See related Spotlight by Zhao and Melenhorst, p. 1040


4 April 2023
Verified
Other
Open access
NINam Gyu Im
Nam Gyu Im
AGAmy Guillaumet-Adkins
Amy Guillaumet-Adkins
MWMegha Wal
Megha Wal
ARAnna J. Rogers
Anna J. Rogers
JFJulia Frede
Julia Frede
BKBirgit Knoechel
Birgit Knoechel
Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell–leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity.See related Spotlight by Zhao and Melenhorst, p. 1040

4 April 2023
Verified
Other
Open access
NINam Gyu Im
Nam Gyu Im
AGAmy Guillaumet-Adkins
Amy Guillaumet-Adkins
MWMegha Wal
Megha Wal
ARAnna J. Rogers
Anna J. Rogers
JFJulia Frede
Julia Frede
BKBirgit Knoechel
Birgit Knoechel
Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell–leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity.See related Spotlight by Zhao and Melenhorst, p. 1040